TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

O, Kosmider; V, Gelsi-Boyer; M, Cheok; S, Grabar; V, Della-Valle; F, Picard; F, Viguié; B, Quesnel; O, Beyne-Rauzy; E, Solary; N, Vey; M, Hunault-Berger; P, Fenaux; Mas V, Mansat-De; E, Delabesse; P, Guardiola; C, Lacombe; W, Vainchenker; C, Preudhomme; F, Dreyfus; OA, Bernard; D, Birnbaum; M, Fontenay

doi:10.1182/blood-2009-04-215814

Public

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

Shared by NobleBlocks on Aug 7, 2009 • 12:00 AM UTC

Authors:

Kosmider O

Gelsi-Boyer V

Cheok M

Abstract

Oncogenic pathways underlying in the development of myelodysplastic syndromes (MDS) remain poorly characterized, but mutations of the ten-eleven translocation 2 (TET2) gene are frequently observed. In the present work, we evaluated the prognostic impact of TET2 mutations in MDS. Frameshift, nonsense...

Discussions